Emilian M.
- Country
- Romania
- Department
- 4022: Neurology
Research Overview
- Efficacy and Safety of Remibrutinib in Patients with Secondary Progressive Multiple Sclerosis: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study
- A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients with Relapsing-remitting Multiple Sclerosis.
- Long-term Safety and Efficacy Evaluation of Ocrelizumab in Multiple Sclerosis Patients from Phase III Studies
Data & Insights
Has run more than one trial at 215 of 444 partner sites.
Specializations
Multiple Sclerosis Research
The investigator specializes in clinical research focused on multiple sclerosis (MS), with particular emphasis on both relapsing and progressive forms of the disease. Their research encompasses innovative therapeutic approaches for treating various MS manifestations.
- Relapsing Multiple Sclerosis (RMS)
- Primary Progressive Multiple Sclerosis (PPMS)
- Progressive Multiple Sclerosis (PMS)
Their work extends to evaluating novel therapeutic agents targeting specific molecular pathways in MS treatment.
Therapeutic Innovations
The investigator's research portfolio includes studies of various novel therapeutic compounds and treatment approaches, including:
- BTK Inhibitors
- Monoclonal Antibodies
- Immunomodulatory Agents
Their work involves evaluating both established and experimental treatments for neurological conditions.
Neurological Disorders
Beyond MS research, the investigator's expertise extends to other neurological conditions, including:
- Central Nervous System Inflammation
- Migraine Prevention
- Nervous System Diseases
Their research encompasses both therapeutic efficacy and long-term safety evaluations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.